InsidersTradesSigma
Track the Lantheus Holdings, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Lantheus Holdings, Inc. has recorded 258 public disclosures. Market capitalisation: €6.6bn. The latest transaction was disclosed on 19 August 2026 (Retenue fiscale). Among the most active insiders: Blanchfield Paul. The full history is accessible without an account.
258
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€34m
111 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Lantheus Holdings, Inc. Hold (neutral), based on 9 analysts. Average price target: US$107.16.
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,770 of 29,063 companies
63.1
score / 100
Value50
Quality76
FCF yld5.3%
Earn yld3.6%
EV/EBITDA17.8x
ROE22%
Gross mgn61%
Net mgn15%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 August 2026
Declarations258 total
2,536 shares@ US$100.910.0039% mcap100.0% of flowCommon StockSEC:0002064832-26-000278:0
463 shares@ US$100.910.0007% mcap65.2% of flowCommon StockSEC:0002064832-26-000277:0
381 shares@ US$96.670.0005% mcap2.8% of flowCommon StockSEC:0002064832-26-000219:0
1,911 shares@ US$83.820.0022% mcap3.3% of flowCommon StockSEC:0002064832-26-000171:0
36,692 shares0Common StockSEC:0002064832-26-000125:0
20,966 shares0Common StockSEC:0002064832-26-000124:0
38,002 shares0Common StockSEC:0002064832-26-000123:0
6,158 shares0Common StockSEC:0002064832-26-000122:0
26,208 shares0Common StockSEC:0002064832-26-000121:0
2,782 shares0Common StockSEC:0002064832-26-000112:0
5,169 shares0Common StockSEC:0002064832-26-000113:0
8,491 shares0Common StockSEC:0002064832-26-000111:0
32,105 shares0Common StockSEC:0002064832-26-000110:0
356 shares@ US$93.4831.5% of flowCommon StockSEC:0002064832-25-000088:0
14,285 shares0Common StockSEC:0002064832-25-000020:0
727 shares@ US$54.900.3% of flowCommon StockSEC:0001062993-25-015276:0
41,000 shares@ US$55.340.035% mcap50.0% of flowCommon StockSEC:0000908834-25-000268:0
41,000 shares@ US$55.340.035% mcap50.0% of flowCommon StockSEC:0000908834-25-000269:0
14,765 shares0Common StockSEC:0001062993-25-014678:0
463 shares@ US$54.18100.0% of flowCommon StockSEC:0001062993-25-014679:0
3,060 shares@ US$53.572.9% of flowCommon StockSEC:0001062993-25-014521:0
518 shares@ US$81.260.8% of flowCommon StockSEC:0001062993-25-012955:0
6,000 shares@ US$78.748.2% of flowCommon StockSEC:0001062993-25-011827:0
14,773 shares@ US$49.930.012% mcap28.2% of flowCommon StockSEC:0001062993-25-011412:0
5,192 shares@ US$81.6235.1% of flowCommon StockSEC:0001062993-25-011413:0
25 of 258 declarations
关于 Lantheus Holdings, Inc.
Lantheus Holdings, Inc. 是一家总部位于美国马萨诸塞州贝德福德的美国放射性药物公司，在纳斯达克上市，股票代码为 LNTH。对于讲法语的投资者而言，该公司处于核医学、诊断成像和靶向治疗的交汇点。其历史可追溯到 1956 年，当时它以 New England Nuclear 的名义成立，这使得 Lantheus 在高度专业化的医疗保健领域拥有悠久的运营历史。如今，该公司定位为一个专注于放射性药物的平台，其战略以 PET 诊断、超声微泡和针对肿瘤学和神经学的开发管线为中心。([lantheus.com](https://www.lantheus.com/about/?utm_source=openai)) 其商业产品组合以具有强大临床相关性和既定市场知名度的产品为核心。PYLARIFY 是一种用于前列腺癌的 PSMA PET 成像剂，是其旗舰产品，被公司描述为美国市场领先的 PSMA PET 成像剂。DEFINITY 是一种超声心动图造影剂，仍然是重要的成熟收入贡献者。Lantheus 还销售 Neuraceq，一种用于阿尔茨海默病评估的淀粉样蛋白 PET 放射诊断剂，同时继续推进 MK-6240 和 NAV-4694 等管线资产。此外，该公司强调其产品的制造、分销和患者获取支持能力。([lantheus.com](https://www.lantheus.com/products/?utm_source=openai)) 从竞争角度来看，Lantheus 受益于在利基市场的可防御地位，在这些市场中，监管执行、同位素供应链、PET 制造能力和报销至关重要。该公司将自己描述为一家领先的专注于放射性药物的企业，其使命是帮助临床医生“发现、对抗和追踪”疾病。其收入基础仍主要以美国为中心，但该公司还在加拿大、德国、瑞典、瑞士和英国设有办事处，支持研究、合作和部分商业活动。([investor.lantheus.com](https://investor.lantheus.com/?utm_source=openai)) 近期公司发展突显了战略转向。在 2025 年和 2026 年，Lantheus 继续将其产品组合重新定位到 PET 放射诊断剂，并将其 SPECT 业务剥离给 SHINE Technologies，从而使公司更加专注于高增长资产。监管里程碑也至关重要：PYLARIFY TruVu 于 2026 年 3 月获得 FDA 批准，LNTH-2501 的 PDUFA 日期延长至 2026 年 6 月 29 日，其他管线项目也通过了关键的监管步骤。同时，对 Life Molecular Imaging 和 Evergreen Theragnostics 的收购扩大了公司的诊断和制造能力，巩固了其成为完全整合的放射性药物领导者的雄心。([investor.lantheus.com](https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-closing-spect-business-sale-shine?utm_source=openai))
